Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

In conclusion, an additional 2 years of treatment with anacetrapib were well tolerated with durable lipid-modifying effects on LDL-C and HDL-C.

Source: Journal of Cardiovascular Pharmacology and Therapeutics - October 15, 2014 Category: Cardiology Authors: Gotto, A. M., Kher, U., Chatterjee, M. S., Liu, Y., Li, X. S., Vaidya, S., Cannon, C. P., Brinton, E. A., Moon, J. E., Shah, S., Dansky, H. M., Mitchel, Y., Barter, P., the DEFINE Investigators Tags: Clinical Studies Source Type: research